What is the quality and effect of Sotorasibu produced by Lucius Pharmaceuticals in Laos?

Sotoraxib (AMG510) developed by Amgen was obtained in2021 in May span>FDAAccelerated Approval for Adults with Non-Small Cell Lung Cancer(NSCLC) whose tumors have KRAS G12C gene mutation and at least one previous systemic therapy.

SotoracibThe recommended dose is 960 mg taken orally once daily. Doctors may need a higher dose if a person has side effects such as liver or lung toxicity, severe nausea or vomiting, severe diarrhea, or other side effects. In some cases, the doctor may decide that treatment needs to be stopped.

Laos Lucius Pharmaceuticals is a formal and qualified pharmaceutical factory in Laos. The production line is strictly controlled. Sotorasibu was launched in Laos in April 2023 with government approval, so the quality of the drug is guaranteed.

In one study124people with KRAS In a study of patients with G12C mutated non-small cell lung cancer (NSCLC) who took 960 mg of sotoraxib daily, 36% /span>people(45people)saw their tumors shrink (at least30%)or disappear. Two people's tumors disappeared, and 43's tumors shrank. The median duration of response was 10 months, with nearly 60% of patients responding for at least 6 months. Additionally, 44% of people (55 patients)’s tumors remained stable, not growing 20% or more or shrinking 30%or more. Overall, soteracib treatment reduced tumor size or inhibited tumor growth in 81% of patients. From the data point of view, the effect is still very significant. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.